Zenas BioPharma, Inc. - 10-Q Filing

Zenas BioPharma reports Q3 2026 financial results featuring significant debt restructuring and ongoing clinical program development.

SEC EDGAR ·

Tickers: $ZBIO

Read the full article at SEC EDGAR

More Regulatory news